Federal and Private Funding Sources for Women's Health Research

In 1993, Congress passed a law requiring the National Institutes of Health to include women in its clinical trials, making inclusion a legal mandate. Before the NIH Revitalization Act, women had not been systematically required to be included in federally funded clinical research. That legislative fix tells you something important about the baseline: many diagnostics and treatments were developed without women in mind and thus failed to account for women's health, and some of those gaps are still working their way through the system today. Now look at what happened to the money since then. Women's health made up 13.5% of NIH's budget in 2005; by 2025, that share had dropped to 10.4%, even as NIH's overall budget grew over those two decades. A review covering fiscal years 2013 through 2023 put the real figure even lower, at 8.8% of NIH research spending actually targeting women's health, according to swhr.org. Women's health didn't get ignored and stay ignored; the share has been shrinking while the pie got bigger, which is arguably worse. That's the landscape this article maps out: where the dedicated funding for women's health research actually sits in 2025, agency by agency, program by program, so researchers and advocates know where to look instead of guessing.

How NIH categorizes and counts women's health spending (and why the numbers are disputed)

NIH tracks its own spending through something called RCDC, the Research, Condition, and Disease Categorization system. Run the numbers through it and you get an official estimate of $4.6 billion in women's health spending for fiscal year 2024, about 10% of NIH's congressional appropriation. That sounds like real money, and it is. But the NASEM committee that reviewed this system found a problem: a large share of grants coded under "Women's Health" weren't actually about a female-specific condition, weren't about a condition more common in women, and didn't involve any sex-difference analysis at all. They just got tagged that way somewhere in the coding process. Which means the $4.6 billion figure is probably an overstatement of what's really going toward research on women's bodies and women's diseases.

Break the whole NIH budget down differently and the picture gets clearer. Roughly 80% of NIH research dollars fund projects that aren't male-specific or female-specific at all; they're general. Of the remaining 20% that does split by sex, women's health gets about 14% and men's health gets about 6%. NIH has indicated that changes to how the Women's Health Research RCDC category is counted represent a methodological shift rather than a funding change; the dollars didn't move, just the math behind how they get labeled.

Here's the practical takeaway for anyone hunting for a grant: don't assume a big, official-sounding category is a door standing wide open. A meaningful chunk of what gets counted as "women's health" research at NIH may have nothing to do with the actual condition or population you're studying, so treat the $4.6 billion figure as a ceiling, not a map.

NIH's Office of Research on Women's Health: what it funds, what it can't require

ORWH has existed since 1990, making it NIH's oldest institutional answer to the question of who's minding women's health research across the agency. Its job is coordination: it publishes and co-sponsors Funding Opportunity Announcements across NIH's institutes and keeps a running portal of what's currently open. If you're trying to find money for a project touching on female-specific biology or sex differences, ORWH is often the first stop.

But coordination isn't the same as authority, and this is where This critique gets sharp. ORWH is a small office. It cannot force any of NIH's 27 institutes and centers to actually conduct sex-and-gender-difference research, and it has no enforcement mechanism to make sure NIH's existing policy on studying both sexes gets followed. It can ask. It can publish. Compelling action is beyond its reach.

Where ORWH does have real reach is workforce development, and this matters more than it might seem at first glance, because funding without trained researchers to spend it is just money sitting unused. ORWH supports or co-sponsors BIRCWH (Building Interdisciplinary Research Careers in Women's Health), SCORE (Specialized Centers of Research Excellence), the Women's Reproductive Health Research Career Development Program, and the Research Scientist Development Program. These are the pipelines that build the next generation of investigators in this field.

The 2024 executive order under President Biden directed ORWH to build one consolidated portal listing open funding opportunities across all 27 NIH institutes, a direct response to a complaint researchers had voiced for years: relevant FOAs were scattered everywhere, and finding them meant checking institute websites one at a time. A related Notice of Special Interest tied to the White House initiative flagged priority areas including autoimmune diseases, cardiovascular disease, Alzheimer's and related dementias, endometriosis, uterine fibroids, menopause, gender-based violence, HIV, and depressive disorders.

The 2024 Biden executive order and the federal investments it triggered

March 2024 brought what the administration called the most far-reaching set of executive actions ever taken on women's health research. The headline ask went to Congress: $12 billion for a new Fund for Women's Health Research housed at NIH. As of this writing, Congress hasn't appropriated that money, so file it under "proposed" rather than "real."

What did get committed and actually launched is still substantial. NIH rolled out a $200 million agency-wide initiative co-chaired by ORWH alongside the National Institute on Aging, NHLBI, NIDA, NICHD, and NIAMS, aimed at how perimenopause and menopause affect heart health, brain health, and bone health across a woman's lifespan. ARPA-H committed $100 million on February 21, 2024, for its Sprint for Women's Health, a program worth its own section below. The Department of Defense put up $500 million for conditions that affect women uniquely, disproportionately, or differently, including ovarian cancer, rheumatoid arthritis, and musculoskeletal injuries. The DoD and VA also stood up a joint collaborative to push women's health research specifically for servicemembers and veterans. Meanwhile, the National Science Foundation sent out a Dear Colleague Letter encouraging researchers to submit proposals tied to women's health.

There's also a parallel channel worth knowing about that often gets overlooked next to NIH's research grants: the HHS Office on Women's Health. OWH funds a different kind of work, projects that share health information, advance policy, train clinicians and the public, and build innovative community programming. This is the infrastructure and outreach layer sitting next to the research itself, distinct from basic science or clinical trials.

ARPA-H's Sprint for Women's Health as a model for high-risk, high-reward funding

ARPA-H exists to fund the kind of research that makes a standard NIH study section nervous. Its whole mandate is built around tolerance for risk and expectation of a genuinely transformative payoff, not incremental progress on a well-worn hypothesis. That's a different animal than most NIH mechanisms, and it changes how researchers should think about applying.

The Sprint for Women's Health launched in February 2024 with $100 million behind it, and the response tells you something about pent-up demand: more than 1,700 submissions came in from over 30 countries. That's a lot of researchers who apparently had ideas waiting for someone to fund them, and it also means competition was fierce.

What does ARPA-H actually want? Conditions where basic understanding still has real holes in it, technology that could genuinely change how care gets delivered rather than just refine an existing pathway, and solutions built to scale rather than stay a boutique intervention in one lab. If your application reads like a careful, incremental extension of known methods, you're pitching the wrong agency. ARPA-H wants disruption and speed to impact; that's a fundamentally different pitch than an R01, and researchers who try to force-fit their standard NIH proposal into an ARPA-H application often find it doesn't land.

One quirk worth flagging: ARPA-H doesn't run on NIH's predictable annual FOA cycle. There's no calendar you can set a reminder around. The only way to know what's coming is to keep an eye on arpa-h.gov directly, because opportunities show up on their own schedule.

Department of Defense and VA funding streams that most researchers don't think to pursue

Here's a genuine blind spot for a lot of academic researchers: the Department of Defense funds a serious amount of women's health research, and you don't need to have a military affiliation to apply for it. That $500 million commitment covers conditions affecting women uniquely, disproportionately, or differently, with ovarian cancer, rheumatoid arthritis, and musculoskeletal injuries named specifically.

The mechanisms that actually move this money are disease-specific programs, each with its own dedicated pot of funding and annual funding cycles.

The DoD-VA Joint Collaborative on Women's Health narrows the focus further, targeting servicemembers and veterans, a population whose health profile and research gaps look different from the general population studied in most academic trials. Academic medical centers, research hospitals, and nonprofits are all eligible to apply to CDMRP programs. The main thing to understand going in is that DoD funding leans applied and translational; a basic science proposal can absolutely get funded, but it needs a clear, explicit line connecting the work back to servicemember or veteran health outcomes. Skip that connection and the strongest basic science proposal in the world goes nowhere.

The NASEM report's case for a new NIH institute and what it would mean for funding

A major report on women's health research made a structural argument rather than just a funding argument. Its recommendation: build an entirely new NIH institute dedicated to women's health research, one with actual authority, its own budget, and enforcement power, which is precisely what ORWH lacks today.

Substantial new investment would be required to stand up the new institute and create a new NIH-wide research fund — proposed figures, not appropriated dollars.

Why not just give ORWH more staff and a bigger budget instead of building something new? The report's logic is that coordination without authority hasn't worked, full stop. NASEM's argument is that a real institute could require compliance across NIH's other institutes, hold and direct its own budget, and set research priorities agency-wide in a way that a coordinating office, no matter how well-run, structurally cannot.

None of this is enacted. It's a recommendation sitting in front of Congress, but it's already shaping the terms of the debate over how NIH's structure and priorities might shift in the next Congress. For researchers, the practical move is to watch legislative and appropriations language closely; any bill that references the NASEM recommendations directly is a signal about where new dedicated funding might eventually flow.

How the Trump administration's funding cuts have disrupted women's health research in 2025

The current budget picture is rougher than the one the 2024 executive order was building toward. The Trump administration's framework proposes cutting NIH's overall budget by close to 40%, and a separate mandate ordered federal health agencies to cut contract spending by at least 35%, which worked out to $2.6 billion in NIH contract cuts.

The most visible casualty was the Women's Health Initiative, and the story is worth sitting with for a moment because of what it reveals about how these cuts actually land. WHI enrolled 161,808 women between ages 50 and 79; more than 42,000 of those women are still participating through extension studies more than three decades later. Researchers affiliated with WHI have published over 2,400 scientific papers off this dataset. Cutting it was a symbolic decision as much as a fiscal one. HHS initially moved to cancel it, then reversed course after pushback from scientists, senators, and public figures, though not before HHS Secretary Robert F. Kennedy Jr. called the reports of the cut "fake news," shortly before an HHS spokesperson confirmed the reversal was real. The longer-term funding outlook for the program's ongoing extension studies remains uncertain.

There's a quieter effect happening alongside the headline cuts, too. Agency employees have reportedly been warned against approving grants that contain words like "women," "trans," or "diversity," which creates a kind of ambient compliance anxiety that touches grants never even flagged for cancellation. You don't have to be the target to feel the chill.

What should a researcher planning an application in 2025 take from all this? Federal money for women's health research still exists, and plenty of it. But the environment underneath it is unstable in a way it wasn't two years ago, which makes spreading applications across multiple federal agencies, private foundations, and state sources less of a nice-to-have and more of a basic survival strategy.

Private foundations and advocacy-linked funders that operate independently of federal budget cycles

Private funders answer to donors and boards, not to Congress, executive orders, or agency-wide spending mandates, which makes them a genuinely more stable source of money whenever the federal picture gets choppy, as it clearly has in 2025.

The Society for Women's Health Research, based in Washington, works as both an advocacy group and a convener, bringing researchers, industry, and policymakers into the same room. SWHR also tracks NIH's funding methodology closely and publishes policy analysis pointing to where the real gaps sit, which makes it a useful resource even for researchers who never apply for SWHR funding directly.

A lot of the largest private dollars in this space aren't organized around "women's health" as a broad category at all; they're organized around single conditions (endometriosis, ovarian cancer, breast cancer, lupus), each with its own dedicated foundation ecosystem. If your research sits inside one of these conditions, the smarter move is mapping directly to that condition's foundation network rather than searching for a general women's health grant that may not exist in the shape you're picturing.

Health systems and academic medical centers increasingly run their own philanthropic arms, and these have gotten more active as federal funding has grown less predictable. They tend to fund pilot studies, small in scope, but useful precisely because that pilot data can turn into the preliminary evidence a federal application needs to be competitive.

Pharmaceutical and medical device companies fund women's health research too, both directly and through foundations, with a lot of activity concentrated in menopause, reproductive medicine, and cardiovascular disease. These partnerships come with transparency requirements worth understanding fully before signing anything, since industry funding carries disclosure obligations that federal grants don't always mirror.

The general pattern across almost all private funders: they move faster than NIH's review cycles, and they're often willing to fund earlier-stage, riskier work. That makes them well suited to generating exactly the preliminary data that later strengthens a federal application.

How to navigate the full funding landscape as a researcher or advocate today

Start with the ORWH consolidated portal. The 2024 executive order directed ORWH to build a single entry point covering open opportunities across all 27 NIH institutes, so check there before manually combing through institute websites one at a time.

From there, match your research area to the agency actually built for it. Menopause, cardiovascular, bone, and brain health work fits NIH's $200 million initiative and related NHLBI and NIA opportunities. Transformative technology or platform-level approaches belong at ARPA-H; keep watching arpa-h.gov since sprints don't run on a fixed calendar. Conditions on the DoD priority list run through CDMRP's annual funding cycles. Policy work, clinician education, and community health programming fit the HHS Office on Women's Health, not NIH's research mechanisms.

Keep the RCDC issue in the back of your mind whenever you're applying for anything that might get coded under "Women's Health." That category is broad, contested, and NASEM has already flagged it as overstated, so the burden is on you to spell out explicitly why your work belongs there rather than assuming the label will do that work for you.

Build a funding portfolio that doesn't rely entirely on any one source. The WHI episode is the clearest possible illustration of why: a 30-plus-year study with over 2,400 published papers to its name still nearly got cut over less than $10 million. If a program with that track record can end up on the chopping block, nothing federal is guaranteed, and private foundations plus institutional funders provide exactly the stability that fills that gap, often by funding the pilot phase that leads into a larger federal grant down the line.

Keep an eye on the NASEM recommendations as they move (or don't) through Congress. If lawmakers act on the proposed new institute or the $15.7 billion funding authorization, the grant landscape shifts fast, and researchers already working in the priority areas NASEM flagged will be best positioned to respond quickly.

And don't treat advocacy as separate from funding strategy. Organizations like SWHR are actively engaged in the legislative process around women's health appropriations, and researchers who plug into those advocacy networks tend to hear about emerging opportunities and policy windows earlier than researchers who wait for the official FOA to post. In a funding environment this unsettled, that early notice might be worth more than any single grant.